INTRODUCTION
Pachyonychia congenita (PC) is a highly debilitating keratinizing disorder caused by mutations in any one of four keratin genes KRT6A, KRT6B, KRT16, or KRT17 (Bowden et al., 1995; McLean et al., 1995; Smith et al., 1998) . The phenotypic and mutational spectrum found in PC is reported by Wilson et al., 2011 . For PC patients, the most painful, disabling feature is focal plantar keratoderma (Leachman et al., 2005; Liao et al., 2007) .
Currently, there are no specific therapies for PC but several research groups are actively working on the development of therapeutics (Kaspar et al., 2011) , in particular using small interfering RNA (siRNA) to inhibit production of the mutant keratin (Hickerson et al., 2006 Leachman et al., 2008; Smith et al., 2008) . This preclinical work recently led to the first proof-of-concept siRNA clinical trial in the field of dermatology, where a PC patient was treated by intradermal injection of a mutation-specific siRNA (Leachman et al., 2010) .
However, intradermal injection proved to be very painful and unsuitable for routine use. Hickerson et al., 2011 , report a promising chemical approach to cutaneous siRNA delivery; however, this is still a long way from clinical application.
An alternative approach is to try to develop pharmacological therapy for PC. Here, the problem of delivery is more tractable, as small-molecule drugs (typically o550 Da) may be used systemically, or with suitable formulation and/or chemical modification, applied topically. However, the biggest hurdle for development of small-molecule therapy for an uncommon inherited disorder such as PC is the extremely high cost of drug development, typically hundreds of millions of dollars (Dickson and Gagnon, 2004; Kaspar, 2005) . Currently, the only drugs available to treat hyperkeratotic disorders such as PC are retinoids, which act via retinoic acid response elements (RAREs) present in the gene promoters of many keratins and other structural molecules of the epidermis to repress gene expression (de The et al., 1990) . These molecules are therefore not very specific for a given keratin or keratin-related gene, and their overall effect is to non-specifically inhibit epidermal differentiation. For this reason, retinoids are not well tolerated in keratinizing disorders because, although they reduce hyperkeratosis, they thin the epidermis and lead to blistering, as well as a range of other side-effects (DiGiovanna, 2010; Ormerod et al., 2010) .
From the International Pachyonychia Congenita Research Registry data, the major PC gene is KRT6A, where about 50% of patients in the registry carry mutations (Smith et al., this issue). Interestingly, the four keratin genes involved in PC differ from other keratins associated with human genetic disorders because they are regulated in both an inducible and constitutive manner. The inducible component includes induction during UV light exposure, wound healing, viral infections, psoriasis, cancer, and other challenges to epithelial tissues (Bernerd et al., 1993; Moll et al., 1994; Komine et al., 2001; Hattori et al., 2002; Wakabayashi et al., 2003; Endo et al., 2008) . Such naturally occurring induction and repression mechanisms led us to hypothesize that certain small molecules may exist that can interfere with this natural induction/repression machinery and thereby modulate the expression of these inducible keratins. The proximal promoter of human keratin 6 (K6) has been studied previously using a clone originally derived from the KRT6B promoter (Ma et al., 1997) . It has been shown that the KRT6B expression is strongly upregulated by IFN-g and downregulated by retinoic acid through IFN-g activation sites and RAREs in the promoter (Tomic-Canic et al., 1996; Freedberg et al., 2001; Hattori et al., 2002) . Through studies of the Keap1/Nrf2 pathway involved in activation of detoxification enzymes such as ketoreductase (Nioi et al., 2003) , it has emerged that the stress-inducible keratins such as K6 can be activated by chemicals, such as sulforaphane (Wakabayashi et al., 2003; Kerns et al., 2007) , that induce gene expression via antioxidant response elements. Bioinformatics analysis of the human KRT6A promoter sequence revealed that this indeed contains RAREs, IFN-g activation site elements, and antioxidant response elements (Table 1; Figure 1a) ; and hence, one would predict that activity of this promoter should be induced by IFN-g and sulforaphane, and inhibited by retinoic acid. Thus, these compounds represent a good starting point to validate a high-throughput chemical libraryscreening assay based on the KRT6A promoter.
One approach to development of new drugs for use in PC or other rare disorders is to screen molecules already approved for human use, in the hope that an existing drug may have a beneficial effect for a new, undiscovered disease indication. This is a high-risk but low-cost approach to finding new drugs to treat rare disorders. Here, we describe such a small-molecule-screening campaign aimed at identifying compounds to inhibit K6a gene/protein expression, as possible means of increasing the pharmacological repertoire for treatment of PC. Unexpectedly, we found that members of the statin family of cholesterol-lowering drugs are able to inhibit human KRT6A promoter activity.
RESULTS
The KRT6A promoter responds as predicted to known inducers/inhibitors A 6,058-bp fragment comprising the promoter region of the human KRT6A gene, extending to the transcriptional start site of the gene, was generated by PCR cloning (Figure 1a ). Bioinformatics analysis showed that this promoter contains a single RARE site close to the cap site, as well as three antioxidant response and seven IFN-g activation site elements scattered throughout the 6 kb promoter fragment ( Figure 1a ; Table 1 ). By transient transfection, the KRT6A-promoterdriven firefly luciferase construct (hereafter described as ''K6a-luciferase'' for brevity) was expressed in the strain of HaCaT cells in use in our laboratory, which we had previously found by RT-PCR, DNA sequencing, and quantitative real-time RT-PCR to express only K6a but not K6b or K6c (data not shown). In all transfections, a standard trace amount of cytomegalovirus (CMV) promoter-driven Renilla luciferase was cotransfected to act as an internal control for cell viability and transfection efficiency. Preliminary transient transfection experiments showed that K6a-luciferase is active in HaCaT cells and primary keratinocytes but shows negligible expression in fibroblasts (data not shown). Figure 1b shows the K6-luciferase activity in HaCaT cells, after normalization against the Renilla luciferase signal in untreated cells and cells treated with IFN-g, sulforaphane, and retinoic acid, at concentrations commonly used in the literature. As expected from studies of the K6b promoter and presence of seven IFN-g activation site elements in the promoter, treatment with 100 U ml À1 IFN-g strongly induced K6a-luciferase expression by approximately 3-fold. Similarly, 10 mM sulforaphane induced K6a-luciferase expression by approximately 2-fold, consistent with the antioxidant response elements present in the promoter. In contrast, 1 mM retinoic acid inhibited K6a-luciferase expression by B50%, consistent with the RAREs present in the promoter. All three agents showed dose-dependent responses (data not shown). Kanno et al, 1993; Decker et al, 1997; and Contursi et al, 2000;  and RARE consensus sequence from Perlmann et al, 1993; Radoja, 1997; and Umesono et al, 1991. Thus, the K6a-luciferase construct appeared to behave as expected based on predicted inducers/repressors. For convenience and reproducibility in a high-throughput-screening context, a stable HaCaT clone was generated via puromycin selection. A clone showing good levels of constitutive K6a-luciferase expression that responded in an identical manner to these agents, as described above (Figure 1b ), was chosen for chemical library screening (data not shown).
Small-molecule library screening identified nine confirmed inhibitors of KRT6A
The chemical library chosen for screening was the National Cancer Institute (NCI) 2,522 diversity set, which consists of 2,522 small drug-like chemical compounds. After initial screening of all compounds at a concentration of 20 mM, 110 compounds were found that decreased K6a-luciferase expression by 40% compared with untreated controls. Of these, 59 compounds decreased K6a-luciferase activity by 450% after normalization to Renilla luciferase expression. In addition, 61 compounds increased K6a promoter activity by B50% after normalization, which were not considered further here. An additional 146 compounds up-or downregulated K6a promoter activity but were found to have cytotoxic effects, and therefore were discarded from subsequent analysis. All hit compounds were retested in triplicate using the K6a-luciferase assay and were also counterscreened against a CMV-driven luciferase construct to eliminate false positives, such as inhibitors of luciferase enzymatic activity, rather than K6a promoter activity or general inhibitors of transcription/translation. Following counterscreening and hit validation, nine confirmed hits remained that inhibited K6a promoter activity by 450%, as exemplified in Figure 2a . An independent sample of all these compounds was sourced and in all cases, the activity was retained, further validating these hit compounds (data not shown). Of these, eight were chemical structures that were not closely related to known drugs and are not discussed further here; however, one of the validated hits, compactin (Brown et al., 1978) , is the precursor of the cholesterol-lowering statin class of drugs currently in widespread clinical use (Miller, 1999) .
Statins inhibit KRT6A basal and inducible promoter activity
As shown in Figure 2b , simvastatin was able to inhibit K6a-luciferase activity to a similar degree to the initial validated hit compound, compactin. The level of inhibition of the K6a-luciferase reporter was also similar to that seen with retinoic acid (Figure 1b ). Figure 2c shows the effect of simvastatin on actual K6a protein expression in HaCat cells by western blotting. K6a protein expression was reduced compared with DMSO (vehicle) control, but the effect was less marked than with 1 mM retinoic acid ( Figure 2c ). In a separate experiment, quantification of western blots was performed using the Li-Cor Odyssey infrared imaging system (Li-Cor, Cambridge, UK). Specifically, K6a protein expression, normalized against an internal actin standard, was substantially inhibited in a dosedependent and time-dependent manner ( Figure 2c ). Importantly, we did not observe inhibition of K5 or K14 by western blotting (data not shown), indicating that the inhibitory effect has some degree of specificity. Other statins tested included pravastatin, fluvastatin, lovastatin, and mevastatin, all of which inhibited K6a promoter activity in a similar manner (data not shown). Thus, it appeared that, unexpectedly, statins are somehow able to inhibit expression of the K6a promoter (Figure 2a and b) , which was confirmed at the level of protein expression (Figure 2c and d). For simplicity, simvastatin was employed in all subsequent experiments described here, although very similar effects were seen with other statins (data not shown).
To investigate whether the inhibitory effect of statins was limited to the basal K6a promoter activity or whether statins are also able inhibit inducible expression, simvastatin was used in combination with IFN-g. Two concentrations of IFN-g (25 and 50 U ml À1 ) were shown to upregulate K6a-luciferase in a dose-dependent manner ( Figure 3) ; however, in the presence of simvastatin, not only was this induction completely abolished but also, in addition, K6a-luciferase was reduced to well below the basal expression level. Thus, statins appear to fully block the inducible expression of the K6a promoter as well as its basal activity. approximately 3-fold increase in K6a-luciferase, and 10 mM sulforaphane resulted in an approximately 2-fold increase in K6a expression, whereas 1 mM retinoic acid treatment reduced K6a expression by B50%. Error bars represent standard error of the mean derived from assay replicates. ARE, antioxidant response element; GAS, IFN-g activation site; K, keratin; KRT, keratin gene; K6a-luciferase, KRT6A-promoter-driven firefly luciferase; luc, luciferase; RA, retinoic acid; RARE, retinoic acid response element; Sul, sulforaphane.
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Statins Downregulate K6a Promoter Activity
Inhibition of KRT6A by statins is mediated by the cholesterol pathway
Statins act by competitively inhibiting the enzyme HMG CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase), which is the rate-limiting step in cholesterol biosynthesis, and therefore the prime target for anti-cholesterol therapy (Russell, 1992) . A schematic illustrating key features of the cholesterol biosynthesis pathway is shown in Supplementary  Figure 1 . To determine whether inhibition of K6a promoter activity was due to the effect of statins on inhibiting the cholesterol biosynthetic pathway rather than an off-target effect, e.g., binding directly to a transcription factor involved in control of the K6a promoter, the intermediate in the cholesterol pathway downstream of 3-hydroxy-3-methylglutaryl-CoA reductase, mevalonate (Russell, 1992) , was used to see whether this could rescue K6a promoter activity. Figure 4 shows that addition of mevalonate alone has no appreciable effect on the constitutive expression level of the K6a-luciferase construct. In contrast, mevalonate is able to rescue the inhibition of K6a-luciferase by simvastatin (Figure 4 ). Furthermore, mevalonate is able to rescue simvastatin's inhibition of K6a induction by IFN-g (Figure 4 ). In contrast, addition of cholesterol had no effect on basal K6a promoter activity in the presence or absence of simvastatin, plus or minus IFN-g (data not shown). Overall, these data suggest that the effect of statins on K6a promoter activity is in fact due to inhibition of the mevalonate/cholesterol biosynthetic pathway rather than via an off-target mechanism. The fact that mevalonate, but not cholesterol, can rescue the effects of simvastatin implies that the key determinant in this K6a inhibitory mechanism is a molecule downstream of mevalonate but upstream of cholesterol in this biosynthetic Figure 2 . Small-molecule library screening identified statins as K6a inhibitors. (a) K6a-luciferase expression data were normalized as described in Figure 2 . Compared with untreated cells (K6a-luc), a significant library hit that reproducibly inhibited K6a-luciferase expression by B50% was compactin. (b) As compactin is the precursor from which all cholesterol-lowering statins are synthesized, we tested a number of statins for K6a inhibitory effects. As shown here, SS reduced K6a-luciferase expression by 450% compared with untreated cells (K6a-luc). Error bars represent standard error of the mean derived from assay replicates. (c) Western blotting showed that 24 hours incubation with SS (8 mM) reduces K6a protein expression in HaCat cells compared with mock (DMSO)-treated cells. In all, 1 mM RA was used as a positive control. The blot was reprobed with GAPDH as a loading control. No appreciable effect of SS on K5 or K14 expression was observed (data not shown). (d) In an experiment separate from that of c, above, infrared imaging (Li-Cor Odyssey system) was used to quantify K6a protein expression on western blots, normalizing against an internal actin-loading control. Over a time course of 24-72 hours, SS was seen to inhibit K6a protein expression at both 1 and 8 mM concentrations. The equivalent quantity of DMSO (used to deliver SS) was used as a negative control. Note that the 1 and 8 mM SS samples were run on the same gel but in non-consecutive lanes (as denoted by the bar). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; K, keratin; KRT, keratin gene; K6a-luciferase, KRT6A-promoter-driven firefly luciferase; RA, retinoic acid; SS, simvastatin. K6a-luciferase expression data were normalized as described in Figure 2 . Again, SS (10 mM) reduced K6a-luciferase activity by 450% compared with untreated cells (K6a-luc). Two different doses of IFN-g (25 and 50 U ml À1 ) strongly induced K6a expression in a dose-dependent manner; however, addition of 10 mM SS in addition to IFN-g (SS þ IFN 25U; SS þ IFN 50U) not only blocked the 2-to 3-fold induction observed but also reduced K6a-luciferase expression below the basal level (K6a-luc). Thus, statins inhibit both the constitutive and inducible expression of the K6a promoter. Error bars represent standard error of the mean derived from assay replicates. K, keratin; KRT, keratin gene; K6a-luciferase, KRT6A-promoter-driven firefly luciferase; luc, luciferase; SS, simvastatin.
pathway. The most obvious candidates are components of the isoprenylation pathways, which are important posttranslational modifications of G-proteins, which in turn are key signaling molecules.
Effect of statins on KRT6A activity is mediated by isoprenylation
The two main isoprenoid modifications of proteins are farnesylation (mediated by farnesyl pyrophosphate, FPP, by the activity of farnesyl transferase) and geranylgeranylation (mediated by geranylgeranyl pyrophosphate, GGPP, through the action of geranylgeranyl transferase), as reviewed (Russell, 1992; McTaggart, 2006) and shown in Supplementary Figure 1 . To see whether either of these pathways downstream of mevalonate was involved in the K6a inhibitory effect of statins, we added FPP or GGPP to the K6a-luciferase assay to see if these could rescue the inhibition. FPP was unable to rescue simvastatin's inhibition of basal and IFN-ginduced K6a promoter activity (data not shown); however, GGPP was able to rescue the effect of simvastatin on K6a ( Figure 5 ). These data implicate geranylgeranylation as a key factor in the downregulation of K6a promoter by statins. Specifically, it has been shown that the induction of certain lymphocyte-specific genes such as CD40 by IFN-g can be blocked by statins. Furthermore, JAK/STAT signaling is an important pathway involved in IFN-g signal transduction (Gough et al., 2008) , where inhibition of CD40 by statins has been shown to be dependent on the Stat1 transcription factor (Lee et al., 2007) . To investigate whether Stat1 is involved in inhibition of the K6a promoter by statins, we employed a proprietary, validated siRNA against Stat1 to see whether this, like statins, also inhibits K6a promoter activity. Western blotting with a Stat1 monoclonal antibody confirmed (i) that Stat1 is normally expressed in HaCaT cells and (ii) that the siRNA is highly efficacious in knocking Stat1 protein levels down to o20% (data not shown). In HaCaT cells, Stat1-specific siRNA was shown to inhibit K6a-luciferase expression in a dose-dependent fashion (Figure 6 ). Moreover, use of both simvastatin and Stat1 siRNA showed a synergistic inhibition of K6a-luciferase activity (Figure 6 ), consistent with inhibition of Stat1 by two independent mechanisms, i.e., degradation of Stat1 mRNA by siRNA and inhibition of Stat1 gene expression by statins via an unknown pathway.
DISCUSSION
Overall, the data presented here show that a cholesterollowering family of drugs, the statins, can inhibit expression of both basal and IFN-g-inducible activity of the keratin K6a promoter. Importantly, K6a inhibition was confirmed at the protein level (Figure 2c and d) . The precise pathways whereby statins inhibit K6a remain unknown, but here, we have gained some preliminary mechanistic insights through . The inhibitory effect of statins on the K6a promoter acts via the geranylgeranylation pathway. K6a-luciferase expression data were normalized as described in Figure 2 . Again, SS (10 mM) can be seen to reduce K6a-luciferase activity by 450% compared with untreated cells (K6a-luc). To investigate which, if any, isoprenoid species downstream of mevalonate was involved in the inhibitory effect of statins on K6a, key intermediates were used to attempt rescue. Addition of 1 mM GGPP alone had little effect on K6a-luciferase expression; however, GGPP completely rescued the reduction in K6a expression mediated by simvastatin (SS þ GGPP). Likewise, GGPP rescued IFN-g induction of K6a expression (SS þ IFN þ GGPP). Error bars represent standard error of the mean derived from assay replicates. GGPP, geranylgeranyl pyrophosphate; K, keratin; KRT, keratin gene; K6a-luciferase, KRT6A-promoter-driven firefly luciferase; luc, luciferase; SS, simvastatin.
www.jidonline.org 5 the use of siRNA against candidate genes, rescue of expression using pathway intermediates and specific kinase inhibitors. Our data clearly show that the inhibitory effects of statins on K6a are dependent on Stat1 transcription factor. Interestingly, a similar inhibitory effect has been shown in lymphocytes for another IFN-g-inducible gene, CD40 (Lee et al., 2007) . We have shown that the K6a inhibitory effect of statins is due bona fide inhibition of the cholesterol/mevalonate biosynthesis pathway rather than an off-target effect (Figure 4) , and interestingly, that this effect can be rescued by mevalonate but not cholesterol itself. Mevalonate is a key molecule in biosynthesis of the isoprenoids, the farnesyl and geranylgeranyl groups added to many G-proteins posttranslationally, such as members of the Rho and Ras families of small guanosine triphosphate-binding proteins, which are key signaling molecules and prime suspects in the immunomodulatory effects of statins (Smaldone et al., 2009) . Our data strongly suggest that it is the geranylgeranylation pathway rather than the farnesylation pathway that is responsible because GGPP ( Figure 5 ) can rescue K6a promoter inhibition by statins, but not FPP (McTaggart, 2006) .
Only in recent years, through the availability of both commercial and non-profit chemical compound libraries (such as the free NCI library used here), coupled with the increased availability of robotics suitable for high-throughout screening, has the advent of drug discovery been seen in an academic context, outside of the biopharmaceutical industry. Our study illustrates two key outcomes of academic drug discovery. First, fresh insights have been gained into the signaling pathways that control keratin expression. As there was no previous obvious clue that keratin gene expression was in any way dependent upon the cholesterol biosynthetic pathway, this somewhat surprising result opens up a new avenue for research into the control of keratin gene expression. Second, and importantly, we have identified an already approved, widely used, and inexpensive drug that might prove to be of use in a neglected inherited skin disorder or group of disorders, immediately opening up the possibility of clinical trials. This circumvents the hundreds of millions of dollars required to develop a drug from scratch, which is unfeasible in an ultra-rare disorder. Because of the rarity of PC and related keratinizing disorders, a chemical library screen based on a simple reporter gene promoter assay is something which the profit-driven pharmaceutical industry is likely to have considered to be too high risk in relation to potential return on the investment; however, this makes an ideal academic drug discovery project. In the future, it is likely that there will be closer collaboration between academia and industry in drug development (Vallance et al., 2010) .
We are continuing our efforts to elucidate the precise mechanism whereby statins inhibit K6a gene expression. However, given the excellent safety profile of statins, we are already involved in open-label clinical trials, with recruitment of a small case series of mutation-defined PC patients identified through the International Pachyonychia Congenita Research Registry. These trials will make use of both systemic and topically formulated statins. While it is highly unlikely that statins will show complete specificity for keratins, their general anti-inflammatory effects might also be useful in inhibiting the process of hyperkeratosis, whose underlying pathomechanisms remain poorly understood, but is thought to involve inflammatory factors such as tumor necrosis factor-a. Even if only partially effective, the use of statins in the treatment-keratinizing disorders such as PC might complement other broad-spectrum drugs such as retinoids. It is also possible that a combination therapy of low-dose systemic or topical retinoids, supplemented by statins, may prove to be more effective.
In conclusion, we have identified statins as potential K6a inhibitory drugs, facilitating a range of low-cost, safe clinical trials in the orphan disease PC.
MATERIALS AND METHODS

Promoter constructs
A 6,058 bp DNA fragment comprising the KRT6A promoter sequence upstream of, and including the transcription start site, was generated from genomic DNA of a normal, healthy control individual using primers PRM3.L (5 0 -TTCCTAGCCATGTTGTGTGT TC-3 0 ) and PRM3.R (5 0 -GAGGGAAGAGAAGCAGGACTAG-3 0 ). This fragment was cloned into plasmid pCR2.1 (Invitrogen, Paisley, UK) and fully sequenced. The full-length insert from a sequence-verified clone was subcloned into the pGL4.21 promoterless vector containing a humanized, high-turnover firefly luciferase gene (luc2P ; Promega, Southampton, UK) using KpnI and XhoI. A control plasmid was generated by subcloning the CMV promoter (BamHI/BglII fragment) from pcDNA3 (Invitrogen) into pGL4.21 (BamHI site). The pRL-CMV plasmid (Renilla luciferase driven by the CMV promoter) was obtained from Promega.
Cell lines
The HaCaT cell line was obtained from Professor Birgit Lane's Laboratory, School of Life Sciences, University of Dundee, UK, originally derived from human adult skin keratinocytes (Boukamp et al., 1988) . HaCaT cells were maintained in Gibco DMEM (Invitrogen, Paisley, UK) supplemented with 10% keratinocytes, Gibco) at 37 1C with a 5% CO 2 atmosphere. Figure 6 . Stat1 transcription factor, known to be involved in IFN-c signaling, is linked to K6a expression. Stat1 has been linked to expression of IFN-ginducible genes in lymphocytes, e.g., CD40. To see whether Stat1 was linked to K6a expression, we used a specific siRNA for Stat1. K6a expression was inhibited by Stat1 siRNA in a dose-dependent manner (siRNA 7-67 nM). When SS was used in combination with the Stat1 siRNA, the dose-dependent inhibitory effect increased. It has been suggested that statins inhibit expression of Stat1 via an unknown pathway (Lee et al., 2007) . Our data are consistent with this, as action of statins at the transcriptional level synergizes with degradation of the Stat1 mRNA. Error bars represent standard error of the mean. K, keratin; siRNA, small interfering RNA; SS, simvastatin.
Transfection
For transient transfection of HaCaT or fibroblasts, cells were plated in 96-well plates at a density of B1 Â 10 4 cells per well in 100 ml of DMEM with 10% fetal calf serum 24 hours before transfection. These conditions routinely gave 70% confluency at the time of transfection. In all, 0.05 mg of plasmid DNA, with or without 0.005 mg pRL-CMV Renilla plasmid, was complexed with 0.15 ml Fugene 6 (Roche, West Sussex, UK) in 4.85 ml of DMEM with no fetal calf serum or antibiotics. DNA-Fugene 6 complexes were mixed gently and incubated at room temperature for 20 minutes before adding to cells. For stable transfection, HaCaT cells were transfected with linearized plasmid (KRT6A promoter in pGL4.21, above) in 10 cm dishes using a scaledup version of the transfection protocol and clones selected using 1 mg ml À1 puromycin (Sigma-Aldrich, Poole, UK).
Dual-luciferase reporter assay system
At 24 hours after transfection, medium was removed and cells in 96-well plates were rinsed in phosphate-buffered saline solution (Invitrogen). Cells were lysed in 20 ml 1 Â luciferase lysis buffer (Dual-Luciferase Reporter Assay System, Promega) at room temperature for 15 min. Both firefly and Renilla luciferase activities were measured by LUMI Star OPTIMA luminometer (BMG Labtech, Aylesbury, UK) according to manufacturer's protocol.
Western blotting
Total protein extracts of HaCat cells were subjected to Coomassie blue staining and western blotting, as described previously . Keratin expression was detected by immunoblotting using 1 hour incubations of the following primary antibodies: 1:200 dilution anti-K6 (Ks6.KA12; Progen Biotechnik, GmbH, Heidelberg, Germany); 1:1,000 anti-K14 (LL001); and 1:10,000 dilution anti-K5 (BL18). All antibodies were kindly donated by EB Lane, College of Life Sciences, University of Dundee, Dundee, UK. On western blots, protein bands were either subjected to enhanced chemiluminsecence staining or, alternatively, were detected and quantified using a Li-Cor Odyssey infrared protein imager according to the manufacturer's recommended protocols (Li-Cor, Cambridge, UK), and data normalized against an internal actin standard.
Reagents
The NCI 2,522 chemical library was obtained from the NCI, National Institutes of Health, Bethesda, MD. IFN-g, simvastatin, pravastatin, fluvastatin, lovastatin, and mevastatin were purchased from Calbiochem (San Diego, CA). Retinoic acid, DL-mevalonate, cholesterol, GGPP, and FPP were obtained from Sigma-Aldrich. Sulforaphane was kindly provided by Professor John Hayes (Ninewells Medical School, Dundee, UK). Stat1 siRNA and antibody were purchased from Cell Signaling Technology (Beverly, MA).
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